The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Phase Ib/IIa study of AZD4573 and acalabrutinib in patients with R/R DLBCL
Gareth Gregory, MBBS, PhD, FRACP, FRCPA, Monash University, Monash Health, Melbourne, Australia, discusses a Phase Ib/IIa study evaluating AZD4573, a novel CDK9 inhibitor, in combination with acalabrutinib in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (R/R DLBCL; NCT04630756). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Roche: Consultancy, Honoraria, Speakers Bureau; Novartis: Consultancy; Janssen: Consultancy.
